Meglumine acridone acetate

In chronic hepatitis C, Cycloferon is not mentioned in AASLD/IDSA HCV Guidance or EASL 2020. The standard of care is direct-acting antivirals (DAAs): sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and other combinations achieving sustained virological response above 95 % in 8–12 weeks.

ICD-10: B18.2 · ICD-11: 1E51.1

URI resolves spontaneously. Symptomatic care is the only approach supported by international guidelines. 'Immunomodulator' drugs are not part of this list.

ICD-10: J00 · ICD-11: CA00

Cycloferon is absent from international COVID-19 guidelines. It appears in Russian regional outpatient protocols but lacks a systemic evidence base. Benefit is not confirmed by independent multicentre RCTs.

ICD-10: U07.1 · ICD-11: RA01.0

First-line therapy for herpes simplex remains aciclovir, valaciclovir, and famciclovir. Cycloferon is not mentioned in international protocols.

ICD-10: B00 · ICD-11: 1F00.Z

Cycloferon (meglumine acridoneacetate), marketed by Polisan, is promoted as an immunity agent and interferon inducer for colds and other infections. International clinical guidelines (WHO, NICE, IDSA) do not include the drug; the FDA, EMA, and AEMPS have not approved it. No independent international clinical studies exist. If cycloferon was recommended, consider seeking a second opinion.

Cycloferon for influenza is not mentioned in WHO, IDSA, NICE, or CDC guidelines. Antiviral options with demonstrated efficacy in independent RCTs are oseltamivir, zanamivir, and baloxavir.

ICD-10: J10-J11 · ICD-11: 1E32